C4 Therapeutics, Inc.
CCCC · Healthcare · $368M
After-hours $3.330.00%
Price
$4.34
$3.13
Jul 1, 26Sep 29, 26
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
RevenueOperating IncomeNet Income
9/'26
Revenue$9M+32.8%
6/'26 vs prev quarter
Company Health
Market Cap$368M
Operating Margin-319.0%
Cash on Hand$254M68.9% of market cap
Free Cash Flow$-85M-23.2% of market cap
Short Float 48.0% · biweekly · settled 26.09.15
Among 327 Biotechnology peers
LowMedianHigh
PSR9.9xmedian 11.4xPBR1.4xmedian 2.0xROE-41.0%median -54.5%C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting5d ago
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?7d ago
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual MeetingSep 3
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue EstimatesAug 11
